Cargando…
Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center
BACKGROUND AND AIMS: The standard treatment of non-metastatic anal squamous cell carcinoma (ASCC) consists of chemotherapy with mitomycin (MMC) plus 5-fluorouracil (5FU) for 1–2 cycles concomitant with pelvic radiotherapy. Subsequent studies introduced cisplatin (CDDP) combined with 5FU, with unclea...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364808/ https://www.ncbi.nlm.nih.gov/pubmed/32728394 http://dx.doi.org/10.1177/1758835920940945 |
_version_ | 1783559905292058624 |
---|---|
author | Rotundo, Maria Saveria Zampino, Maria Giulia Ravenda, Paola Simona Bagnardi, Vincenzo Peveri, Giulia Dell’Acqua, Veronica Surgo, Alessia Trovato, Cristina Bottiglieri, Luca Bertani, Emilio Petz, Wanda Luisa Fumagalli Romario, Uberto Fazio, Nicola |
author_facet | Rotundo, Maria Saveria Zampino, Maria Giulia Ravenda, Paola Simona Bagnardi, Vincenzo Peveri, Giulia Dell’Acqua, Veronica Surgo, Alessia Trovato, Cristina Bottiglieri, Luca Bertani, Emilio Petz, Wanda Luisa Fumagalli Romario, Uberto Fazio, Nicola |
author_sort | Rotundo, Maria Saveria |
collection | PubMed |
description | BACKGROUND AND AIMS: The standard treatment of non-metastatic anal squamous cell carcinoma (ASCC) consists of chemotherapy with mitomycin (MMC) plus 5-fluorouracil (5FU) for 1–2 cycles concomitant with pelvic radiotherapy. Subsequent studies introduced cisplatin (CDDP) combined with 5FU, with unclear results. We evaluated the doublet capecitabine (C) and CDDP as a possible alternative to MMC-5FU regimen concomitant with intensity-modulated radiation therapy (IMRT). PATIENTS AND METHODS: We carried out a retrospective study on 67 patients affected by stage I–III ASCC, treated with CDDP (60–70 mg/m(2) every 21 days for two courses) plus C (825 mg/m(2) twice daily for 5 days/week) chemotherapy concomitant with IMRT for curative intent. RESULTS: At a median follow up of 41 months, the clinical complete response calculated at the 6-month time-point (6-moCR), the 6-month objective response rate and the 6-month disease control rate were 93%, 94%, and 99%, respectively. Disease-free survival rates at 1, 2, and 3 years were 89%, 87%, and 85%, while the overall survival rates at 1 and 2 years were 100% and 95%. The colostomy-free survival rates were 90% at 1 year and 88% at 2 years. Grade 3–4 acute adverse events were reported in 61% of patients; predominantly skin toxicity (46%) and limited hematological toxicity (12%). CONCLUSION: In this retrospective study, chemotherapy with C plus CDDP concomitant with IMRT proved safe and effective, and may represent a possible alternative option to standard MMC-containing regimen for curative intent. |
format | Online Article Text |
id | pubmed-7364808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73648082020-07-28 Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center Rotundo, Maria Saveria Zampino, Maria Giulia Ravenda, Paola Simona Bagnardi, Vincenzo Peveri, Giulia Dell’Acqua, Veronica Surgo, Alessia Trovato, Cristina Bottiglieri, Luca Bertani, Emilio Petz, Wanda Luisa Fumagalli Romario, Uberto Fazio, Nicola Ther Adv Med Oncol Original Article BACKGROUND AND AIMS: The standard treatment of non-metastatic anal squamous cell carcinoma (ASCC) consists of chemotherapy with mitomycin (MMC) plus 5-fluorouracil (5FU) for 1–2 cycles concomitant with pelvic radiotherapy. Subsequent studies introduced cisplatin (CDDP) combined with 5FU, with unclear results. We evaluated the doublet capecitabine (C) and CDDP as a possible alternative to MMC-5FU regimen concomitant with intensity-modulated radiation therapy (IMRT). PATIENTS AND METHODS: We carried out a retrospective study on 67 patients affected by stage I–III ASCC, treated with CDDP (60–70 mg/m(2) every 21 days for two courses) plus C (825 mg/m(2) twice daily for 5 days/week) chemotherapy concomitant with IMRT for curative intent. RESULTS: At a median follow up of 41 months, the clinical complete response calculated at the 6-month time-point (6-moCR), the 6-month objective response rate and the 6-month disease control rate were 93%, 94%, and 99%, respectively. Disease-free survival rates at 1, 2, and 3 years were 89%, 87%, and 85%, while the overall survival rates at 1 and 2 years were 100% and 95%. The colostomy-free survival rates were 90% at 1 year and 88% at 2 years. Grade 3–4 acute adverse events were reported in 61% of patients; predominantly skin toxicity (46%) and limited hematological toxicity (12%). CONCLUSION: In this retrospective study, chemotherapy with C plus CDDP concomitant with IMRT proved safe and effective, and may represent a possible alternative option to standard MMC-containing regimen for curative intent. SAGE Publications 2020-07-15 /pmc/articles/PMC7364808/ /pubmed/32728394 http://dx.doi.org/10.1177/1758835920940945 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Rotundo, Maria Saveria Zampino, Maria Giulia Ravenda, Paola Simona Bagnardi, Vincenzo Peveri, Giulia Dell’Acqua, Veronica Surgo, Alessia Trovato, Cristina Bottiglieri, Luca Bertani, Emilio Petz, Wanda Luisa Fumagalli Romario, Uberto Fazio, Nicola Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
title | Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
title_full | Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
title_fullStr | Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
title_full_unstemmed | Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
title_short | Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
title_sort | cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364808/ https://www.ncbi.nlm.nih.gov/pubmed/32728394 http://dx.doi.org/10.1177/1758835920940945 |
work_keys_str_mv | AT rotundomariasaveria cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT zampinomariagiulia cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT ravendapaolasimona cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT bagnardivincenzo cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT peverigiulia cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT dellacquaveronica cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT surgoalessia cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT trovatocristina cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT bottiglieriluca cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT bertaniemilio cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT petzwandaluisa cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT fumagalliromariouberto cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter AT fazionicola cisplatinpluscapecitabineconcomitantwithintensitymodulatedradiationtherapyinnonmetastaticanalsquamouscellcarcinomatheexperienceofasingleresearchcancercenter |